Trial Profile
A prospective, open label, observational study treatment adherence, disease control and satisfaction of multiple sclerosis patients treated with natalizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 11 Dec 2015 New trial record